Sales & Marketing News | pharmaphorum

News

Packaged Pills in aluminium blisters stacked on each other

J&J, wholesalers see an end to their opioid liability hangov...

Johnson & Johnson and the 'big three' US pharma wholesalers say they are close to finalising a $26 billion settlement that could allow them to finally put years of litigation over their

News

GSK names its consumer health spinoff Haleon

GlaxoSmithKline's consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker.<

News

Judge shuts down Servier's argument that NHS should have sto...

A London high court judge ruled this week that the damages paid to the NHS for an anticompetitive action by French pharma company Servier will not be reduced, despite an eyebrow-raising bid

News

Bayer triples sales forecast for prostate cancer drug Nubeqa

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastati

News

Tablets on dollar bills (treatment, addiction, aging - concept). Vintage effect.

Collegium agrees $604m buyout of pain specialist BDSI

Collegium Pharma has expanded its pain franchise though a deal to acquire BioDelivery Sciences International (BDSI), which has three FDA-approved drugs and a new migraine therapy due to lau

News

Ipsen plans sale of consumer health business for €350m

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year.

J&J, wholesalers see an end to their opioid liability hangov...

GSK names its consumer health spinoff Haleon

Judge shuts down Servier's argument that NHS should have sto...

Bayer triples sales forecast for prostate cancer drug Nubeqa

Collegium agrees $604m buyout of pain specialist BDSI

Ipsen plans sale of consumer health business for €350m

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks